Spyre Therapeutics price to book ratio SYRE

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 7.2×
10-year median: 2.6×
Against its 10-year history: 90th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.2× to 13.2×
Peer median: 9.2×

Spyre Therapeutics' price to book ratio is 7.2× as of Oct 23, 2026.

That is above its ten-year median of 2.6×, higher than on 90% of days in the last ten years.

Over that time it ranged from 0.2× in Apr 2023 to 13.2× in Jul 2026.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.2×	4.4×	13.2×
2025	5.6×	1.4×	5.7×
2024	3.7×	3.4×	10.0×
2023	0.9×	0.2×	1.2×
2022	0.4×	0.3×	2.2×
2021	2.3×	1.8×	3.5×
2020	2.8×	1.9×	10.9×
2019	2.9×	1.5×	3.7×
2018	2.9×	1.6×	5.3×
2017	1.6×	0.8×	1.6×
2016	0.9×	0.8×	1.4×

Against its peers

Companies in Drug Manufacturers - General nearest Spyre Therapeutics' size, closest first, today.

Company	Price to book ratio
SYRESpyre Therapeutics	7.2×
TGTXTG Therapeutics	13.7×
ALKSAlkermes plc.	4.0×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
AMRXAmneal Pharmaceuticals	197×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
BMRNBiomarin Pharmaceutical	1.7×
JAZZJazz Pharmaceuticals	2.9×
INDVIndivior Pharmaceuticals	n/m
Peer median	9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Spyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.